Why is Family Office money so hard to find for life science companies?

As an early advocate for the importance of the family office in the biotech financing landscape, I have learned from recent experience what many entrepreneurs already know.  Raising money from family offices is hard. While there are several challenges to attracting...

To Tax, or Not to Tax, That is the Question.

The first half of 2017 has been relatively strong for the medical technology space.  In the public sector, MedTech stocks have been performing well.  Many believe this stems from the potential permanent repeal of the Affordable Care Act and its associated medical...

Q2 2017 Trends in Life Science Finance

Our Q2 report analyzes current trends of 2017, and how life science strategic deal activity has been performing in recent years. In this report you can find an overview and analysis of: Biopharma public indices Biopharma IPOs Deal activity for strategic partnership...

Helping to Ensure Success After the Deal

One of my favorite places to hang out in Tokyo is the Apple Store in the Ginza area.  It is a beautiful four-story venue, complete with a theater (where one can sit and receive non-stop sessions on all of Apple’s products) and, of course, the Genius Bar.  One of the...